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Abstract: Expansions of trinucleotide repeats (TNRs) are associated with genetic disorders such as
Friedreich’s ataxia. The tumor suppressor p53 is a central regulator of cell fate in response to different
types of insults. Sequence and structure-selective modes of DNA recognition are among the main
attributes of p53 protein. The focus of this work was analysis of the p53 structure-selective recognition
of TNRs associated with human neurodegenerative diseases. Here, we studied binding of full length
p53 and several deletion variants to TNRs folded into DNA hairpins or loops. We demonstrate that
p53 binds to all studied non-B DNA structures, with a preference for non-B DNA structures formed by
pyrimidine (Py) rich strands. Using deletion mutants, we determined the C-terminal DNA binding
domain of p53 to be crucial for recognition of such non-B DNA structures. We also observed that
p53 in vitro prefers binding to the Py-rich strand over the purine (Pu) rich strand in non-B DNA
substrates formed by sequence derived from the first intron of the frataxin gene. The binding of p53
to this region was confirmed using chromatin immunoprecipitation in human Friedreich’s ataxia
fibroblast and adenocarcinoma cells. Altogether these observations provide further evidence that p53
binds to TNRs’ non-B DNA structures.
Keywords: trinucleotide repeat; p53; non-B DNA; DNA hairpin; DNA–protein; frataxin
1. Introduction
Wild type p53 (p53) is an important transcription factor that plays a significant role in the
prevention of tumor cells development and is widely known as “the guardian of the genome and
epigenome” [1,2]. As a response to potentially oncogenic conditions, the tumor suppressor p53 protein
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regulates expression of many target genes involved in cell cycle control, DNA repair, senescence and
apoptosis. Biological functions of p53 are possible due to its binding to DNA in a sequence-specific
or structure-selective manner. The central DNA binding domain (DBD, aa 102–292) is responsible
for sequence-specific binding to p53 consensus sequence (p53CON), which consists of two copies
of sequence 5′-PuPuPuC(A/T)(T/A)GPyPyPy-3′ separated by 0–13 base pairs [3]. At the C-terminus
of p53 protein, there is a second autonomous DNA binding domain (CTDBD, aa 363–382), which is
capable of structure-selective recognition of free DNA ends [4], or supercoiled DNA [5]. The capability
of p53 to bind non-B DNA structures, e.g., DNA triplex, quadruplex and DNA cruciform, has been
described [6–9].
Repetitive sequences containing trinucleotide repeats (TNRs) such as (CTG)n·(CAG)n,
(CGG)n·(CCG)n and (GAA)n·(TTC)n represent conformationally flexible genomic DNA sequences with
an ability to form non-B DNA structures, especially during DNA metabolism [10–13]. These types of
repeats can form a variety of hairpins, loops, intramolecular triplexes, quadruplexes and slipped-strand
structures, which have been implicated in TNR expansion via molecular mechanisms involving DNA
replication, recombination or repair [12–14]. At least 40 human genetic neurological, neurodegenerative,
and neuromuscular diseases are associated with the expansion of TNR sequences [12,15,16].
One example of TNR associated disorder is Huntington’s disease connected to CTG·CAG repeat
expansion [17]. Interestingly, high binding affinity of p53 to non-B conformation of CTG·CAG
trinucleotide repeats was revealed in previous reports [18,19]. In the case of hairpin formed by
CTG-strand, p53 binding improved proportionally to the size of the repeats from one to seven
repeats [19]. Another example of TNR associated disease is Friedreich’s ataxia, which is connected
with an unstable (GAA)n·(TTC)n trinucleotide repeat expansion in the first intron of the frataxin gene
(FXN, chromosome 9q13 [12,20,21]). The correlation between the number of (GAA)n·(TTC)n repeats
and the Friedreich’s ataxia phenotype severity is well established. Normal chromosomes have 5–30
GAA repeats in which <12 repeats are called short normal alleles and >12 are called long normal
alleles [22]. According to experimental model and repeat length, sequences from (GAA)n·(TTC)n
repeat were observed to form different non-B DNA structures: slipped DNA with DNA-loops, DNA
triplexes, DNA-hairpins or parallel duplexes [23–27].
In this work, we show the binding affinity of p53 for non-B DNA structures formed by GAA,
TTC, CTG and CAG trinucleotide repeats. Furthermore, for the first time, we detect p53 interacting
with the trinucleotide repeats region of the first intron of frataxin gene folded in vitro into non-B DNA
structures and p53 binding to this region in adenocarcinoma cells (MCF7) and Friedreich’s ataxia
fibroblast cells (FXN 4654) upon p53 stabilization. These observations provide further evidence that
it could be useful to investigate how p53 influences genetic instabilities of TNR sequences that are
important for some human diseases.
2. Results and Discussion
2.1. Interaction of p53 with Non-B DNA Structures Derived from TTC, GAA, CTG and CAG Trinucleotide
Repeat Sequences
Formation of non-B DNA structures inside TNR sequences is correlated to TNR expansion,
that is in turn associated with the progression of a range of human diseases [26]. Previous studies of
CTG·CAG tracts (11 repeats) showed that p53 exhibits preferential recognition of hairpin DNA over
their linear forms, canonical (CTG·CAG) duplexes or mismatched (CTG·CTG; CAG·CAG) duplexes [18].
In our study, we focused on GAA·TTC TNRs associated with Friedreich’s ataxia, on differences in p53
recognition of the pyrimidine and purine strands of the GAA·TTC repeat and also on comparison
to other repeats. We examined TNR sequences containing 11 repetitions, which is in the normal,
non-disease range for the Friedreich’s ataxia region [16]. TNR sequences were locked into a non-B
DNA form (NB), as previously described for the CTG·CAG repeat [18] and schematically portrayed in
Figure 1 and Table S1. This non-B DNA form represents a slipped strand intermediate and may contain
several non-B DNA structural motifs: three-way junctions, hairpins, and mismatched duplexes formed
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by self-annealed TNR strands or loop structures. The binding of p53 protein was examined for each
strand of GAA·TTC and CTG·CAG repeats locked within non-B DNA structures, by EMSA (Figure 1A,
lanes 4–15) and ELISA (Figure 1C). To compare the amount of p53 bound to Py-strand (TTCNB,
Figure 1A, lanes 4–6) with protein bound to Pu-strand (GAANB, Figure 1A, lanes 7–9), unbound free
DNA (usually forming sharper bands, the intensities of which are easier to evaluate, compared to often
more smeary bands of the bound DNA fraction) was monitored. The p53 preference for TTCNB was
evident from the amount of free DNA after p53 binding (Figure 1A, compare lane 6 to lane 9). Similarly,
as in the case of CAG·CTG repeats and in agreement with a previous study [18], CTG hairpin (CTGNB)
was preferred substrate for p53 protein over CAG hairpin form (Figure 1A, compare lanes 12 and 15).
A relatively strong difference in p53 interaction with Pu- and Py-strands of repeat was also observed
with the TNB (Figure 1B, lanes 10–12) and ANB (Figure 1B, lanes 13–15), which were “hairpin-like”
structures formed by (T/A)33 tracks locked in a loop in the same way as the TNR sequences. Within all
of this data, it is important to note that p53 bound the most strongly to the p53 consensus sequence
(CON) (Figure 1A lanes 1–3). To better characterize differences in affinities of p53 to different non-B
DNA structures and CON, we used ELISA (Figure 1C) followed by quantitation using a specific DO1
antibody as was recently described for p53-telomeric quadruplex DNA-binding [6]. With this system
(Figure 1C), we confirmed the EMSA data that p53 binds to TTCNB and TNB with higher affinity than
to an equivalent GAANB and ANB.
To roughly check the proper formation of designed structures, i.e., TNR hairpin or unfolded
region within a double-helical DNA, we performed enzymatic footprint of the structures (Figure 1D,E).
T7 endonuclease I, specific for mismatched base-pairs and junctions, gave a strong signal at the
junction between the TNR part and the locked terminal B-DNA part for both TTCNB and GAANB.
Single-strand specific P1 nuclease cleaved at optimal concentration only the TNR part, indicating
proper formation of locked B-DNA, but without significant site preference, indicating unfolded TNR
part, for both structures.
In summary, our results show p53 binding to slipped strand mimicking intermediates formed
by TNR repeats with preference for TTC repeats over their purine-rich counterparts. Although the
p53 binding to some TNRs has been studied previously, here the effects of TTC non-B DNA structure
were studied for the first time. We compare p53 binding to TTC with other TNR non-B DNA (GAA,
CTG and CAG), with ELISA and EMSA results showing that affinity for the TTC repeat was higher
than for the previously published CTG and GAA non-B DNA structures [18,19].
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Figure 1. Full length p53 binding to non-B DNA formed by repetitive sequences. Analysis of p53 
binding to DNA molecules containing various sequences and structures. DNA sequences are 
provided in Table S1. In panels (A) and (B), radiolabeled oligonucleotides (1 pmol) were bound by 
p53 in binding buffer in the presence of non-specific DNA competitor (75 ng, BSK/SmaI) and analyzed 
on a 6% 0.5× TBE polyacrylamide gel. The p53/DNA ratios are given per p53 tetramer. (A) DNA 
molecules are slipped strand mimicking substrates formed by trinucleotide repeat sequences (11 
repeats of TTC, GAA, CTG or CAG) and a duplex p53 consensus sequence (CON). (B) DNA molecules 
formed by TANB, TNB, ANB, and DNA sequence nonspecific for p53 (dsLOCK, ssLOCK). (C) p53 
binding to biotinylated oligonucleotides by ELISA, portrayed are mean values and SD. The 
dissociation constants (Kd) calculated per p53 tetramer are indicated. (D,E) Polyacrylamide gels 
showing resolved products of TTCNB (D) and GAANB (E) enzymatic or chemical cleavage with 
increasing concentration of T7 endonuclease I (left), P1 nuclease (middle) and potassium 
permanganate followed by piperidine treatment (right). Right panels show schematic drawings of 
formed structures. Small arrows indicate preferential cleavage by T7 endonuclease I. 
2.2. Role of p53 Core and C-Terminal DNA Binding Domains in TNR Non-B DNA Recognition 
To examine the roles of both p53 DNA binding domains (Figure 2A) in p53 TNR slipped-strand 
mimicking substrate recognition, we analyzed the DNA interactions of isolated p53 core domain 
(p53CD, aa 94–312, Figure 2B) and p53 C-terminal segment (p53CT aa 320–393; containing 
p53CTDBD and tetramerization domains, Figure 2C,D). Binding of p53CD and p53CT to CTGNB 
hairpin, TTCNB and TNB was compared with their binding to the CON (Figure 2B,C, lanes 4–6) and a 
non-specific DNA sequence (NON, Figure 2B, C lanes 1–3). Importantly, although p53CD was able 
to form a specific complex with the consensus sequence under the experimental conditions (Figure 
2B, lanes 4–6), it was unable to form a stable complex with any of the structure-specific substrates 
(Figure 2B, lanes 7–15). In contrast to p53CD, binding of p53CT to non-B DNA substrates (CTG 
hairpin, TTCNB and T-loops) was clearly selective over binding to duplex CON or NON substrates 
Figure 1. Full length p53 binding to non-B DNA formed by repetitive sequences. Analysis of p53
binding to DNA molecules containing various sequences and structures. DNA sequences are provided
in Table S1. In panels (A,B), radiolabeled oligonucleotides (1 pmol) were bound by p53 in binding
buffer in the presence of non-specific DNA competitor (75 ng, BSK/SmaI) and analyzed on a 6% 0.5×
TBE polyacrylamide gel. The p53/DNA ratios are given per p53 tetramer. (A) DNA molecules are
slipped strand mimicking substrates formed by trinucleotide repeat sequences (11 repeats of TTC,
GAA, CTG or CAG) and a duplex p53 consensus sequence (CON). (B) DNA molecules formed by
TANB, TNB, ANB, and DNA sequence nonspecific for p53 (dsLOCK, ssLOCK). (C) p53 binding to
biotinylated oligonucleotides by ELISA, portrayed are mean values and SD. The dissociation constants
(Kd) calculated per p53 tetramer are indicated. (D,E) Polyacrylamide gels showing resolved products
of TTCNB (D) and GAANB (E) enzymatic or chemical cleavage with increasing concentration of T7
endonuclease I (left), P1 nuclease (middle) and potassium permanganate followed by piperidine
treatment (right). Right panels show schematic drawings of formed structures. Small arrows indicate
preferential cleavage by T7 endonuclease I.
2.2. Role of p53 ore a d - er inal i i i s i - ec ition
To examine the roles of bot 53 i i ai s ( i re 2 ) in p53 TNR slipped-strand
mimicking substrate recognition, e analyze the interactions of isolated p53 core domain
(p53CD, aa 94–312, Figure 2B) and p53 C-terminal segment (p53CT aa 320–393; containing p53CTDBD
and tetramerization domains, Figure 2C,D). Binding of p53CD and p53CT to CTGNB hairpin, TTCNB
and TNB was compared with their binding to the CON (Figure 2B,C, lanes 4–6) and a non-specific DNA
sequence (NON, Figure 2B, C lanes 1–3). Importantly, although p53CD was able to form a specific
complex with the consensus sequence under the experimental conditions (Figure 2B, lanes 4–6), it was
unable to form a stable complex with any of the structure-specific substrates (Figure 2B, lanes 7–15).
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In contrast to p53CD, binding of p53CT to non-B DNA substrates (CTG hairpin, TTCNB and T-loops)
was clearly selective over binding to duplex CON or NON substrates (Figure 2C). The ELISA system
(Figure 2D) confirmed p53CT binding to TNR with often higher affinity than to p53CON, it also
demonstrated p53CT preference for TTCNB over GAANB. Overall, the C-terminal region of p53,
containing CTDBD and tetramerization domain, seems to be chiefly responsible for p53 TTCNB
recognition. This corresponds to data acquired by Walter et al. [18], who observed decreased p53
binding to CTG or CAG hairpins upon obstructing the p53 C-terminus by PAb421, an antibody
mapping to the C-terminal region.
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2.3. Binding of Wild-Type p53 to GAA·TTC Sequence in scDNA 
To confirm that p53 can bind to TTC repeat sequence also in scDNA an EMSA in agarose gel 
was performed. Binding of p53 to scDNAs with (pPGM1) or without p53CON (pBSK) was compared 
with derived plasmids containing (GAA)18·(TTC)18 sequence (pPGM1/TTC and pBSK/TTC). As 
expected, binding of p53 to pPGM1 (Figure 3, with p53CON, lanes 11–15) was much stronger than 
binding to pBSK (Figure 3, lanes 1–5). Introducing TTC sequence did enhance p53 affinity for both 
plasmids. The used TTC sequence is a relatively weak binding site since it could not by itself 
(pBSK/TTC) provide the same affinity as an established p53CON (pPGM1), although the affinity will 
possibly be affected by TNR length.  
The observed binding improvement to p53CON when in combination with TTC (pPGM1/TTC) 
encourages further exploration into non-B DNA structures as modulators of p53 regulated 
transcription near p53 consensus sites. In the case of the T.A.T type of triplex, we have previously 
shown that triplex forming sequence in supercoiled plasmid reporter can enhance transcription from 
Figure 2. Role of core and C-terminal DNA binding domains in p53 non-B DNA recognition.
(A) Full-length p53 (p53; DBD—central DNA binding domain; TD—tetramerization domain;
CTDBD—C-terminal DNA binding domain) and its deletion variants p53CD (aa 94–312) and p53CT (aa
320–393) were used in this study. (B,C) EMSA analysis of p53CD (B) and p53CT (C) binding to CTGNB,
TTCNB, TNB, nonspecific (NON) and p53 specific sequence (CON). Radiolabeled oligonucleotides
(1 pmol) were bound by p53CD (B) or p53CT (C) in binding buffer in the presence of non-specific DNA
competitor (50 ng BSK/SmaI) and analyzed on polyacrylamide gels (for more details see Figure 1).
The p53/DNA ratios are given per p53 tetramer. (D) ELISA analysis of p53CT binding to biotinylated
oligonucleotides: non-B DNA substrates CTGNB, TTCNB, GAANB, ANB, TNB and p53 specific sequence
(CON). Portrayed are mean values and SD. Dissociation constant values (Kd) are calculated per p53CT
tetramer in the presence of 2 ng/well of competitor DNA.
Our results showing that the C-terminal DNA binding domain with the tetramerization domain
is crucial f r TNR non-B DNA high affinity binding relat well with our previous studies n other
non-B DNA structures, e.g., G-quadruplex [6,9] and T.A.T DNA triplex [8].
2.3. Binding of Wild-Type p53 to GAA·TTC Sequence in scDNA
To confirm that p53 can bind to TTC repeat sequence also in scDNA an EMSA in agarose gel was
performed. Binding of p53 to scDNAs with (pPGM1) or without p53CON (pBSK) was compared with
derived plasmids containing (GAA)18·(TTC)18 sequence (pPGM1/TTC and pBSK/TTC). As expected,
binding of p53 to pPGM1 (Figure 3, with p53CON, lanes 11–15) was much stronger than binding to
pBSK (Figure 3, lanes 1–5). Introducing TTC sequence did enhance p53 affinity for both plasmids.
The used TTC sequence is a relatively weak binding site since it could not by itself (pBSK/TTC) provide
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the same affinity as an established p53CON (pPGM1), although the affinity will possibly be affected by
TNR length.
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Figure 3. p53 binding to ( )18·(TTC)18 sequence in scDNA. Wtp53 binding to supercoiled plas ids
pBS , pBS /TT , pP 1 and pP 1/TT as studied by E S in agarose gel. tp53 protein as
incubated ith scDNA (pBSK and pBSK/TTC 100 ng, lanes 1–10), scDNA containing p53CON (pPGM1
and pPGM1/TTC 100 ng, lanes 11–20) in p53/DNA molar ratios 0.5, 1, 1.5 and 2 at 4 ◦C. EMSA was
performed at 4 ◦C.
The observed binding improvement to p53CON when in combi ation with TTC (pPGM1/TTC)
encourages further exploration into non-B DNA structures as modulators of p53 regulated transcription
near p53 consensus sites. In the case of the T.A.T type of triplex, we have previously shown that triplex
forming sequence in supercoiled plasmid reporter can enhance transcription from a neighbor p53
consensus sequence [8]. In our current work, we detect p53 selective binding to scDNA with TTC
repeats indicating that this type of slipped DNA can serve as a non-B DNA binding motif for p53 in
complex molecules.
2.4. Analysis of p53 Interaction with TNR Region from the First Frataxin Intron in Cells
Expansion of GAA·TTC repeat in the first intron of the frataxin gene is associated with Friedreich’s
ataxia [21]. Using the strategy used to prepare other clamped TNRs, each strand from this region
(Table S1) was locked to a non-B DNA structure. Pu-rich strand (FXN-ANB) and Py-rich strand
(FXN-TNB) constructs were used for p53 binding analysis by EMSA. The formation of locked non-B
DNA structures of FXN-TNB and FXN-ANB was confirmed by enzymatic cleavage by T7 endonuclease
I and P1 nuclease (Figure 4B), similarly as in Section 2.1. The binding of p53 to FXN-TNB (Figure 4A,
lanes 4–6) was stronger than to FXN-ANB (Figure 4A, lanes 7–9). The affinity for TTCNB (Figure 4A,
lanes 10–12) lies between FXN-TNB and FXN-ANB.
To determine if endogenous p53 binds to GAA·TTC expansion region in the first intron of FXN we
chose this GAA·TTC rich sequence for ChIP analysis in adenocarcinoma cell line MCF7 and Friedreich’s
ataxia fibroblast cell line FXN 4654. To detect the p53-DNA binding in cells, we used semiquantitative
PCR analysis (Figure 4C) and qPCR (Figure 4D), both employing primers that map the first intron of
FXN and controls. Detection of p53 binding to P21 promoter was used as a positive control and binding
to P21 exon was used as negative control (Figure 4C). The GAA·TTC rich frataxin region was bound in
the investigated MCF7 cells and we observed increase of p53 binding after p53 stabilization in response
to nutlin-3 (NUT) and doxorubicin (DOX) treatment (Figure 4C,D). In case of p53-DNA analysis in
Friedreich’s ataxia fibroblast cell line FXN 4654 we were able to detect binding to p21 promoter region
and FXN GAA·TTC rich sequence by ChIP-qPCR analysis. Data confirmed the increased region
occupancy of P21 and FXN genes after p53 stabilization by NUT and DOX in both tested cell lines
(Figure 4D). Taken together, ChIP analysis has confirmed the EMSA results, connecting p53 and TNR
associated with Friedreich’s ataxia disease. Interestingly, when probing other genomic GAA·TTC rich
regions, p53 bound to the intragenic region on chromosome 2q (Figure 4C, 2q) but not the last intron of
RNF150 gene (Figure 4C, 4q). Bioinformatics blast analysis revealed (Figure S1) that both p53 bound
regions (FXN and 2q) contain DNase I hypersensitivity sites, usually indicating transcriptionally active
chromatin. In contrast, 4q GAA·TTC rich region did not contain such sites and was unbound by p53
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(Figure 4C). The nucleosome occupancy, methylation status and other factors are probably responsible
for the differences in p53 recognition of the three investigated TTC rich segments in human genome.Molecules 2019, 24, x FOR PEER REVIEW 7 of 14 
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treatment (right). Right panels sho sche atic dra ings of for ed structures. Small arrows indicate
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GAA·TTC repeat containing 4q region. In vitro p53 binding as analyzed in CF7 cells without and
with nutlin-3/doxorubicin 4 hours treatment with DO1 antibody against p53 (lanes 4, 7 and 10), with IgG
as negative control ChIP (lanes 3, 6 and9), and with positive input control (1/15 input for ChIP, lanes 2,
5 and 8). (D) ChIP data for MCF7 cells treated by 5 µM nutlin-3 (NUT) and 1 µM doxorubicin (DOX)
and FXN 4654 cells treated by 5 µM nutlin-3 (NUT) and 0.1 µM doxorubicin (DOX) were acquired by
qPCR and presented as percent recovery of input DNA by the specific DO1 antibody. A control without
addition of antibody is shown.
As for frataxin, a p53-responsive element was recently fo nd in the roximal FXN promoter [28,29]
and FXN was identified as a p53 target gene. The dysfu ction of p53 by mutation in c ncerous cells was
found to decrease the expression of frataxin and deregulate mitochondrial iron homeostasis, similarly
to Friedreich’s ataxia disease [29]. However, the previously investigated area did not cover the TNR
region, which as we show may add a new regulatory feature to the p53–frataxin interplay.
Molecules 2019, 24, 2078 8 of 14
To examine whether the human FXN expression is regulated by p53 in tumor adenocarcinoma
cell line (MCF7) and non-tumor cells (fibroblast BJ and Friedreich’s ataxia fibroblast cell line FXN
4654), the cells were treated by nutlin and doxorubicin and RT-qPCR was carried out. As shown in
Figure S2A,B in MCF7 cells, the level of FXN mRNA and p21 mRNA markedly increased in dependence
on time of treatment (4 h or 16 h) and drugs; doxorubicin strongly increasing oxidative stress response
or nutlin primarily stabilizing p53 protein level. The strongest activation of FXN expression was
observed after 16 h treatment by nutlin. RT-qPCR analysis in non-tumor fibroblast cell lines BJ and
FXN 4654 after 4 h treatment showed FXN repression in FXN 4654 cells (Figure S2C) and no influence
on FXN expression in contrast to p21 after nutlin or doxorubicin treatment in BJ cells (Figure S2D).
Our expression analysis of FXN in different cell lines showed that further studies are necessary to
understand the p53 role in frataxin biology. Frataxin repression after doxorubicin (oxidative stress
inducer) treatment was observed previously in normal cells (cardiomyoblasts) [30].
The role of oxidative stress in Friedrich ataxia’s cells [31] and p53 function in stress response have
to be considered. The reduction of frataxin expression is associated with increased oxidative stress
and cell damage, accumulation of iron in mitochondria [32]. These factors can strongly influence p53
function by oxidative damage of protein. The central domain of p53 protein is sensitive to cysteine
oxidation which leads to reduction or abolishment of sequence specific interaction with p53 consensus
element [33] but p53 non-B DNA structure recognition is partially maintained for oxidized p53 as was
observed for G-quadruplexes [6] or supercoiled DNA [33]. We do show an increase in p53 occupancy on
frataxin TNR regions when treated with oxidative stress inducing agent doxorubicin. The C-terminal
domain directed binding may represent a potential mechanism by which p53 could regulate frataxin
under oxidative stress.
2.5. Future Prospects of p53 and TNR Non-B DNA Structures
In cancer genomes, (GAA)n repeats, together with (AT)n, and (GAAA)n, constitute the most
frequent repeats at translocation breakpoints, which represent an intrinsic risk factor for genomic
rearrangements [34]. Interestingly, unlike CNG repeats, GAA repeats display unique behavior during
TNR repeat expansion: a) strict strand orientation dependence of the replication stalling; b) GAA
repeats expansion occurs once they reach a certain threshold [35]. As p53 is involved as a transcription
factor and also by direct interactions with several relevant proteins in processes that might be important
in TNR stability such as homologous recombination, mismatch repair, replication [2,36,37], it is a future
prospect to investigate p53 influence on TNR stability.
The GAA triple repeat expansion in Friedreich’s ataxia is directly responsible for the transcriptional
silencing of frataxin gene [21]. Nowadays two model potential mechanisms are considered to be
responsible for this reduction of frataxin expression: a) the formation of non-B DNA structures
(including RNA_DNA hybrid non-B structures or GAA triplexes) and b) heterochromatin formation [32].
Inhibition of the frataxin transcription process by non-B DNA conformation was observed in vitro and
in vivo [32,38].
The significance of the observed p53 preference for Py-rich TNR non-B DNA structures is
proposed to be associated with a mechanism of gene silencing in Friedreich’s ataxia (Figure S3).
The transcriptional block of Pol II on long GAA·TTC repeats occurs via the TTC strand [32]. So far,
we can only speculate if the recently observed p53 regulation of DNA-binding function of Pol II [39],
can also influence Pol II transcription of frataxin gene. The transcriptional weak spot represented
by the extruded TTC strand is however preferentially recognized by p53, as is shown in the current
study (Figure S3). The triplex DNA formation is another proposed mechanism of Pol II transcriptional
block on frataxin TNR. In our previous work, we observed preferential p53 recognition of DNA T.A.T
triplex. We used the luciferase reporter assay to detect the effect of a T.A.T triplex on p53 driven
transcription [8]. We observed T.A.T triplex dependent enhancement of reporter plasmid activation
with p53CON sequence and triplex forming sequence by luciferase reporter assay. We also observed
that the same sequence can block transcription of reporter plasmid if it contains only T.A.T triplex
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motif in supercoiled reporter [8]. Any future reporter assays with TNR have to take into account
the influence of DNA topology because DNA supercoiling is a necessary condition for non-B DNA
formation [8]. The requirement for a threshold level of DNA supercoiling may be the reason why the
study of the influence of CTG·CAG repeat track on a linear luciferase reporter did not show profound
effect for p53 [18].
Further studies are needed to understand the precise function of p53 TNR non-B DNA recognition
in relation to the development of Friedreich’s ataxia or other diseases coupled with TNR expansion.
The ability of p53 to interact with two DNA binding domains makes the protein very flexible in
terms of its physiological functions. The C-terminal DNA binding domain is mainly responsible for
high affinity non-B DNA recognition by p53 [6,8,9] and, for the first time, our work shows that this
domain is crucial for TNR non-B DNA recognition. It is expected that the ability of p53 to recognize TNR
non-B DNA is conserved in the majority of hot spot cancer mutant p53 proteins [40]. About 90% of TP53
mutations are localized to the central part of gene, the majority of mutant p53 will still have functional
C-terminus, so they will be able to recognize non-B DNA structures formed by TNR, as already shown
for hot spot R273H mutant p53 to recognize CTG non-B DNA structures [18], which may be a reason
why p53 status was not associated with Friedreich’s ataxia. In contrast, C-terminal mutants in lysine
residues are expected to not recognize TNR non-B similarly to truncated mutant p53 without 30 last
amino acids [6,9,41].
In summary, we show that non-B DNA structures formed by TNR (TTC, GAA, CTG, CAG) and
simple T-repeat are recognized by p53. Moreover, p53 prefers non-B DNA structures formed by the
pyrimidine-rich strands of the investigated repetitive sequences and that the intact C-terminus is
responsible for high p53 affinity to TNR non-B DNA structures.
3. Materials and Methods
3.1. Oligonucleotides
The sequences of oligonucleotides used in this study are presented in Table S1, and these were
purchased from Sigma-Aldrich (Praha, Czech Republic). DNA hairpin or DNA loop structures were
prepared as described in [18,19]. Briefly, Lock-F oligonucleotide was mixed with the repeat containing
complementary strands in buffer (10 mM Tris-HCl, pH 8; 0.1 mM EDTA and 50 mM KCl) and placed
in a heating block at 95 ◦C for 5 min. DNA substrates were allowed to cool slowly and anneal for a
minimum of 3 hours. For EMSA Lock-F was 5′-labeled by T4-DNA polynucleotide kinase (NEB) with
32P-gamma ATP. For ELISA Lock-F was biotinylated at the 3′ end.
3.2. Recombinant Plasmids
Plasmids allowing controlled expression of human p53 proteins pT7-7wtp53 (full length wild
type p53, aa 1–393), pGEX-4Tp53CD (GST-p53CD, aa 94–312) and pGEX-2TKp53CT (GST-p53CT,
aa 320–393) were described previously [5]. Nonspecific competitor (pBSK/SmaI) was prepared by SmaI
restriction enzyme (Takara, Japan) cleavage of pBluescript SK II- (pBSK, Stratagene). pPGM1 was
derived from pBSK by cloning 20bp p53 consensus sequence into HindIII restriction site. Plasmids
pBSK/TTC and pPGM1/TTC were prepared by cloning into the EcoRI/SmaI restriction site, establishing
a continual 18× GAA·TTC repetition. All plasmids were isolated from E. coli bacterial strain TOP10
(Stratagene) and verified by sequencing.
3.3. Purification of p53 Recombinant Proteins
Full length p53 and isolated DNA binding domains (p53CD (aa 94–312) and p53CT (aa 320–393))
were purified via their GST tag according to a protocol described previously [5,40].
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3.4. EMSA in Polyacrylamide Gels
Electrophoretic mobility shift assays were performed with 32P-radiolabeled oligonucleotide probes
(1 pmol) mixed with p53 proteins and incubated in binding buffer (5 mM Tris-HCl, pH 7.6; 0.5 mM
EDTA; 0.5 mM DTT; 0.01% Triton-X100 and 50 mM KCl) in the presence of 50 or 75 ng pBSK/SmaI DNA
competitor for 15 min on ice to reach equilibrium. Samples were loaded onto a 6% polyacrylamide
gel containing 0.5× Tris-borate-EDTA (TBE) buffer. After 30 min electrophoresis (at 6 V/cm) the gels
were dried, and DNA was detected by autoradiography using Typhoon FLA 9000 (GE Healthcare).
Representative gels from at least three repetitions are shown.
3.5. EMSA in Agarose Gels
Wtp53 protein was incubated with 100 ng scDNA in p53/DNA molar ratios 0.5–2 in binding buffer
(5 mM Tris-HCl, pH 7.6; 0.5 mM EDTA; 0.5 mM DTT; 0.01% Triton-X100 and 50 mM KCl) for 15 min
at 4 ◦C. Samples were loaded onto a 1% agarose gel containing 0.33× Tris-borate-EDTA (TBE) buffer.
After 5 h electrophoresis (at 4–6 V/cm) agarose gels were stained with ethidium bromide (EtBr) and
photographed. Representative gel from at least three repetitions is shown.
3.6. ELISA
A 96-well Immuno Plate (SPL LIFE SCIENCES) was coated overnight at 37 ◦C with 5 ug/mL
streptavidin (PROSPEC) in 1× PBS (137 mM NaCl; 2.7 mM KCl; 8 mM Na2HPO4 and 2 mM KH2PO4)
(50 µL/well). The plate was rinsed with 1× PBS (200 µL/well) and blocked for unspecific binding by 3%
BSA (Sigma-Aldrich) in 1× PBS (2 h, room temperature, 200 µL/well). Next, 0.3 pmol of biotinylated
DNA oligonucleotides (50 µL/well) in 1× TTKD (5 mM Tris-HCl, pH 7.6; 0.01% Triton-X100 and 50 mM
KCl; 0.5 mM DTT) were bound to the plate (1 h, room temperature). The plate was rinsed with 1×
PBST (1× PBS; 0.05% Tween) (200 µL/well) and then pre-incubated protein–primary antibody mixes
(in 2:1 Ab:protein molar ratio in 1× TTKD) were added (50 µL/well). Experiments were performed
with p53 and p53CT; in experiments with p53CT, 2 ng of competitor (pBSK/SmaI) was added per
well, more details in [6,8]. The plate was incubated 20 min at 4 ◦C and rinsed in 1× PBST and three
times in 1× PBS + 0.5% BSA (200 µL/well). Secondary HRP-labeled antibody was incubated on the
ELISA plate for 30 min at 4 ◦C (50 µL/well). The plate was washed in 1× PBST and three times in
1× PBS + 0.5% BSA (200 µL/well), after which 50 µL/well of TMB substrate was added. The TMB
(3,3’,5,5’-Tetramethylbenzidine, Sigma) was dissolved to 1 mg/mL in DMSO (dimethyl sulfoxide).
The working solution was made by diluting 0.6 mL of the DMSO stock with 5.4 mL phosphate–citrate
buffer, pH 5.0, and then adding 1.2 µL of fresh 30% hydrogen peroxide. Absorbance was measured at
370 nm on Synergy H1 (BioTek) and evaluated in GraphPad Prism using hyperbolic or “Hill” equation
fittings. Dissociation constants (Kd) were obtained from at least three independent measurements and
the values are given per tetramer for full length p53 and p53CT.
3.7. Chromatin Immunoprecipitation
Nutlin-3 and doxorubicin were investigated to stabilize the endogenous p53 and subjected to
chromatin immunoprecipitation (ChIP) assays as previously described in [8]. Purified monoclonal
DO1 antibody and IgG (negative control) were used for ChIP. The PCR was performed using
the primers targeting the expected p53 binding site referred to as P21 promoter (p21-chipF:
GCACTCTTGTCCCCCAGGCT; p21-chipR: GGTCTCCTGTCTCCTACCAT) [8], the GAA·TTC loci
of the first intron of the frataxin gene (FXNchip_F1721: GAAAGAGGCAGGCCACGTCCAAG;
FXNchip_R2170C: CATTGGGCGATCTTGGCTTAATGC) and another GAA·TTC rich regions:
intragenic region on chromosome 2q (2q36F: AAAAGGGCAACATGAACTACTG, 2q36R:
ACTTTTGCCCAGAGATAACTC) and intronic region of the RNF150 gene on 4q chromosome
(4q31F: AGCTTTGCTAGGAACCAATATG; 4q31R: TGTCAGATAACTGAACTTGTAC)
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described in [42] and P21 exon region (p21-F: CCTCAAATCGTCCAGCGACCTT; p-21-R:
CATTGTGGGAGGAGCTGTGAAA).
Friedreich’s ataxia skin fibroblast cell line (FXN 4654, ~190 and ~500 GAA repeats, Kerafast) was
grown in DMEM medium supplemented with 15% FBS, penicillin/streptomycin (BioSera) and 1%
MEM Non-essential Amino Acid Solution (100×) (Sigma-Aldrich) and incubated at 37 ◦C with 5% CO2.
Cells were treated for 4 hours with nutlin-3 (5 µM) and doxorubicin (0.1 µM).
Human breast adenocarcinoma cell line MCF7 (HTB-22, ATCC) was grown in DMEM medium
supplemented with 5% FBS and penicillin/streptomycin (Biosera). The medium was supplemented
24 hours before the treatment with higher concentration of FBS (10%) and treated for 4 hours with
nutlin-3 (5 µM) and doxorubicin (1 µM). PCR-based analysis of ChIP DNA was carried out in triplicates
for 25 or 30 cycles, with the following conditions (94 ◦C 2 min; 94 ◦C 1 min; 65 ◦C 1 min 25–30×; 72 ◦C
1 min; 72 ◦C 10 min). qPCR was performed on Rotor-Gene 6000 (Corbett Research) in the standard
program (15 min at 95 ◦C; 15 s, 95 ◦C; 30 s, 60 ◦C; 20 s, 72 ◦C; 10 s, 74 ◦C; 50 cycles) using EvaGreen
(Solis Biodyne) fluorescent dye.
Number of TTC repeat in MCF7 (eight times) and FXN 4654 (~190 and ~500 GAA repeats) cells
was controlled by PCR fragment analysis for ChIP primers and by sequences of this fragment in case
of MCF7 cells.
3.8. Expression Analysis
Cells (normal fibroblast skin cell line BJ (ATCC® CRL-2522™), FXN 4654 and MCF7) were
harvested using trypsin (Biosera) and seeded into 6 cm tissue culture dishes (TPP). After 24 hours cells
were treated with 0.1 µM doxorubicin or 1 µM Nutlin-3 for 4 hours. For RT-qPCR analysis, total RNA
was isolated by applying NucleoSpin RNA II (MachereyNagel, according to the manufactures
instruction) (Düren, Germany) and 2 µg of RNA were reverse transcribed using the High Capacity
RT kit (Applied Biosystems, according to manufactures protocol) (Brno, Czech Republic). PCR was
performed using the EvaGreen (Solis Biodyne) fluorescent dye in the standard program (15 min
95 ◦C; 15 s 95 ◦C, 30 s 60 ◦C, 20 s 72 ◦C, 10 s 74 ◦C; 50 cycles) running in the RotorGene 6000
(Corbett Research). PCR reactions for each sample were repeated in triplicates. The GAPDH
reference gene was used as endogenous control. An absolute quantification of mRNA levels was
done and relatively related to control (with no treatment). The following primer sets were used:
GADPH-QF15: ACAACTTTGGTATCGTGGAAGG; GADPH-QR15: GCCATCACGCCACAGTTTC,
FXN-F: CAGAGGAAACGCTGGGACTCT; FXN-R: AGCCAGATTTGCTTGTTTGG; p21-F:
CCTCAAATCGTCCAGCGACCTT; p-21-R: CATTGTGGGAGGAGCTGTGAAA.
3.9. Enzymatic and Chemical Footprinting
TNR containing sequences were radiolabeled using 32P-gamma ATP and T4 polynucleotide kinase.
Labelled sequences (0.4 pmol) were heated for 5 min at 90 ◦C with 0.5 pmol of lock sequence in 10 mM
Tris-HCl, pH 8 with 50 mM KCl and cooled to room temperature. Formed structures were treated
at 23 ◦C with decreasing amounts of T7 endonuclease I (10 to 2 to 0.4 units) for 30 min, with 10 mM
MgCl2, P1 nuclease (1 to 0.2 to 0.04 units) for 30 min, with 1 mM ZnCl2 or potassium permanganate (2
to 0.4 to 0.08 mM) for 10 min. Potassium permanganate reaction was stopped by β-mercaptoethanol
and oligonucleotides were ethanol-acetate precipitated, treated for 30 min by 1 M piperidine at
90 ◦C and piperidine was removed by extensive lyophilization. DNA from nuclease reactions was
phenol/chloroform extracted and ethanol–acetate precipitated. Thirty kcpm of radiolabeled DNA were
dissolved in formamide loading dye, denatured and loaded on a pre-heated 20% polyacrylamide
denaturing gel with 7 M urea and 1× TBE. Gels were run for 90 min at 45 W in 1× TBE. Results were
visualized by a 2 hour exposition to a PhosphorImager screen and scanned on a Typhoon FLA9000
scanner (GE Healthcare Life Sciences).
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Supplementary Materials: The following are available online, Figure S1: Blat analysis of GAA·TTC rich regions
used for ChIP, Table S1: DNA oligonucleotide sequences used in experiments.
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